1 Unraveling diagnostic co-morbidity makeup of each HF category as

2 characteristically derived by ECG- and ECHO-findings

3

4 Azfar Zaman, MD, Prof¹; Marta Afonso Nogueira, MD²; Erzsebet Szabo, MD³, Aniko Berta-Szabo,

- 5 MD³; Giuseppe Biondi Zoccai, MD, MStat, Prof⁴; Niall Campbell, MD, PhD, FRCP⁵; Georgios
- 6 Koulaouzidis, MD⁶; Dionissios Tsipas, MD⁷; and Istvan Kecskes, PhD⁸.
- 7
- 8 ¹ Newcastle upon Tyne Hospitals NHS Trust, Freeman Hospital, Newcastle University, Newcastle, UK
- 9 ² Consultant Cardiologist Heart Failure and Cardiomyopathies, Department of Cardiology, Cascais
- 10 Hospital, Lusíadas Saúde—UnitedHealth Group, Lisbon, Portugal
- 11 ³ Department of Internal Care, Senta Hospital, Senta, Serbia
- 12 ⁴ Cardiology at Sapienza University of Rome, Sapienza University, Latina, Italy
- 13 ⁵ Department of Cardiology, Manchester University NHS Foundation Trust, Manchester, UK
- 14 ⁶ Department of Cardiology, Pomeranian Medical University, Szczecin, Poland,
- 15 ⁷ Department of Cardiology, Specialty cardiologist At ASL Teramo, Teramo, Italy
- 16 ⁸ Dir. Cardiology Research and Scientific Advancements, UVA Research., Subotica, Serbia,
- 17 Corresponding Author: <u>istvan.kecskes@uvaresearch.com,</u> +381642636882
- 18
- 19 <u>Keywords:</u> Echocardiography; Electrocardiogram; Heart Failure; Primary Care; Bio-signal;
- 20 Cardio-HARTTM

21 Abstract

- 22 Background: Echocardiography (ECHO) is not widely available in primary care, the key
- 23 structural (chamber enlargements) and functional abnormality are not easily available
- 24 precluding the ability to diagnose HF other than through mainly symptomatic means. The
- 25 opportunity for earlier detection of HF is lost.
- 26 **Methods:** Using a unique database, the etiology of HF is explored by prevalence analysis to
- 27 unravel the diagnostic makeup of each HF category. Various relationships and patterns of
- 28 comorbidities have been extracted between the Electrocardiogram (ECG) and ECHO parameters
- 29 that contribute to HF, those relationships are then confirmed and categorized by a Principal
- 30 Component Analysis (PCA). Finally, it was summarized what type of non-invasive ECG-like
- 31 device should be used in primary care to better diagnose HF.
- 32 **Results:-**The sensitivity of abnormal ECHO reaches 92% over the abnormal ECG of 81% in the
- 33 detection of HF. The first five PCA are discovered, which cover 49% of all the variance. Left atrial
- 34 enlargement is the most representative finding in the overall comorbidity rate, which coincides
- 35 with the probability direction of HF (3rd as input, 1st as finding in the coefficients), and reaches
- 36 the highest (250%) prevalence increase in function of decreasing LVEF.
- 37 Conclusions: The core structural and functional abnormalities diagnosed by ECHO with the ECG
- 38 interpretation provide sufficient information to diagnose "consider HF" in primary care.
- 39 This paper overview of a novel bio-signal-based system supported by Artificial Intelligence, able
- 40 to replicate Echo-findings, predict HF and indicates its phenotype, suitable for use in Primary
- 41 Care.

42 **1** Introduction

43 Heart Failure (HF) is a heterogeneous syndrome with various etiologic and pathophysiologic

- 44 factors that define the three main categories, primarily supported by Echocardiogram (ECHO)
- 45 to determine Left Ventricle Ejection Fraction (LVEF) and to a lesser degree by Electrocardiogram
- 46 (ECG) as found in guidance and research articles. ^{1,2,3,4,5,6,7,8,9} Failure to understand these
- 47 abnormalities can undermine detection leading to a failure or delay of diagnosis, and
- 48 misdirected treatment.
- 49
- 50 According to recent European Society of Cardiology (ESC) diagnostic guidelines,¹ the
- 51 categorization of HF relies primarily on LVEF: 1) reduced, HFrEF (LVEF ≤40%); 2) mildly-reduced,
- 52 HFmrEF (LVEF between 41% to 49%); and 3) preserved, HFpEF (LVEF of ≥50%). However, LVEF
- as a measure of HF is limited, as LVEF alone it does not explain the underlying disease
- 54 characteristics and conditions, for example, LVEF estimates global function but does not
- 55 indicate Left Ventricular (LV) volume or stroke volume (SV).^{4,10} Also, LVEF is not sufficiently
- 56 sensitive for subtle LV systolic dysfunction (LVSD) caused by regional Wall Motion Abnormality
- 57 (WMA) present in HFpEF, better detected by mitral annular systolic excursion or systolic
- 58 velocities or LV global longitudinal strain (GLS). ^{10,11,12}.
- 59
- 60 Rather, LVEF has to be obtained with an assessment of LVSD and Dilated Cardiomyopathy
- 61 (DCM) supported by many other structural and functional abnormality and pathophysiological
- 62 characteristics, such as Left Atrial Enlargement (LAE), Ventricular Hypertrophy (LVH), and
- 63 Diastolic Dysfunction (DD).^{1,2,3,4,13} In addition, the phenotype of functional abnormalities is
- 64 strongly connected to Atrial Fibrillation (AFib),^{7,8,9,14} coronary artery disease (CAD), WMA, Aortic
- 65 Stenosis (AS), and other valve diseases, e.g., Mitral Regurgitation (MR),¹⁵ as well as Pulmonary
- 66 Hypertension (PH).^{16,17} The measurement of these findings including LVEF are primarily
- 67 obtained from Echocardiography.
- 68
- 69 Not surprisingly, guidelines 1,3,4 make little reference for use of ECG which has the low
- 70 diagnostic capability for HF, primarily due to its poor sensitivity for heart structural
- abnormalities,^{18,19} especially for left atrial enlargement,^{20,21} and poor sensitivity or specificity
- 72 for heart functional abnormalities.^{22,23,24,25} Alone, ECG's inherent diagnostic limitations for atrial
- and ventricular enlargements make it unsuitable for the detection of HF in primary care
- 74 settings.
- 75
- 76 Lacking a suitable device able to detect structural and functional abnormalities required to
- 77 confirm HF and its categories that are also indicated for use in Primary Care. The current
- vinderstanding and prediction of HF at the Primary Care level is typically limited to more
- 79 protracted symptomatic-based assessments leading to a clinical prognosis. Any opportunity for
- 80 the earlier detection of HF is lost.
- 81
- 82 The objective of this study is to discover what type of diseases/abnormalities should be
- 83 detected from bio-signals to support HF diagnosis in Primary Care without ECHO. This study

- 84 investigate the key abnormalities that enable HF classification. First, we explore the etiology of
- 85 each HF phenotype, then investigate various relationships or comorbidities between the ECG
- 86 and ECHO parameters that contribute to HF; and finally, confirm those relationships via a
- 87 Principal Component analysis (PCA), similarly to in.²⁷ Understanding these findings together,
- 88 determines more precisely the underlying physiological nature of abnormal functions, not just
- 89 the symptoms of HF, for each phenotype, and associate them to novel bio-signals.
- 90
- 91 These key abnormalities appear to be addressed by a Breakthrough technology through the use
 - 92 of novel bio-signals and AI that emulates echocardiography findings²⁶.
 - 93

94 **2 Analysis along HF categories**

95 2.1 Background of HF categories

96 2.1.1 HFpEF

97 HFpEF is widely recognized as a heterogeneous disorder, therefore the diagnosis relies on
98 objective evidence of multiple structural and functional abnormalities in conjunction with
99 LVEF≥50%: LVH, LAE, DD (elevated LV filling pressure), and elevated B-type natriuretic peptide
100 (BNP)¹. Based on consensus recommendation from the Heart Failure Association (HFA) the
101 initial HFpEF diagnosis relies on HF symptoms, standard ECG, standard ECHO, and a Natriuretic
102 Peptides test that together comprises the *HFA-PEFF* algorithm ⁴.

103

104 LAE has been associated with abnormal DD,²⁸ since DD contributes to left atrial remodeling ^{29.}

105 In the past, it was labeled "diastolic HF", a suboptimal term given diastolic HF is not present in

all HFpEF⁵. Several complementary pathophysiologic mechanisms exist in HFpEF, including

107 longitudinal LV systolic dysfunction (despite a normal LVEF), PH, abnormal ventricular-arterial

coupling, abnormal exercise-induced vasodilation, extracardiac volume overload, and
 chronotropic incompetence.^{5,30,16,17} A PH relationship is confirmed by the H₂FPEF score study,

110 where the pulmonary artery systolic pressure >35mmHg was selected as one of the score

elements.⁹ CAD, valve diseases, and PH are considered as primary comorbidities of

HF,^{16,31,32,17,15,33,34} and the etiology of HFpEF relies on these abnormalities in the case of non-DD
 type HF.

114

HFpEF in a broader sense can be divided into various types, such as Coronary artery disease HFpEF, Right heart failure-predominant HFpEF, Valvular HFpEF or AFib-predominant HFpEF
 (fully defined in ⁵). This wider definition of HFpEF is advantageous in primary care, since early
 detection of HF is as important as identifying the specific type of HF. However, the advanced
 diagnosis of HFpEF should be differentiated from the alternative causes of dyspnea such as
 HFrEF, valve disease, primary PH, or pericardial effusion ⁴.

121

122 2.1.2 HFmrEF

123 HFmrEF is a recently separated HF class, thus fewer research results are available in the

124 literature. Patients with HFmrEF have a different clinical profile, but one more similar to

125 patients with HFpEF than with HFrEF³⁵; primarily mild LVSD, but with features of DD. The

diagnostic criteria for HFmrEF include relevant structural heart disease, such as LVH or LAE, or

127 DD beside symptoms and the mildly reduced EF (LVEF of 40-49%).¹ HFmrEF is associated with

128 different characteristics and a more favorable prognosis than HFrEF,³⁶ has less comorbidity – as

discovered by our analysis. HFmrEF patients who transitioned to HFrEF were more likely to have

130 LAE including AFib and more comorbidities.³⁷

132 2.1.3 HFrEF

133 HFrEF is a complex clinical condition characterized by structural and/or functional impairment

- 134 of the left ventricle, resulting in a decrease in heart pump function (LVEF \leq 40%)³⁴.
- 135
- 136 HFrEF is most commonly associated with DCM or CAD,³¹ LVSD and moderate AS commonly
- 137 occur together; patients with moderate AS and concomitant LVSD are at high risk for clinical
- events including all-cause death, hospitalization for HF, and aortic valve replacement.³² Non-
- ECG detectable abnormalities such as severe valve regurgitations, including MR,¹⁵ AR,³³ TR ³⁴
 increase the mortality of HF patients.
- 141
- 142 ECG in HFrEF patients is almost always abnormal, and most patients typically have a minimum
- of two but more typically three ECG abnormalities, with ECG LVH criteria being the most
- 144 common abnormality.³⁸ AFib and HF often occur together, and their combination is associated
- 145 with increased morbidity and mortality compared with each disorder alone.³⁹
- 146

147 2.1.4 ALVSD

148 Although not an HF phenotype, mild Asymptomatic LVSD (ALVSD) is a predictor of adverse

149 events mainly in subjects with combined DD.⁴⁰ Patients with ALVSD ("Stage B" according to

150 ACC/AHA of HF, NYHA CLASS I) have approximately half the mortality rate (5% annualized) of

- 151 those with overt symptoms of HF, but their risk of death is 5 to 8 times higher than a normal
- age-matched population.^{41,42} Patients with ALVD are at high risk for developing HF, therefore,
- 153 they should be considered potential HF patients.
- 154

In the Cardio-Phoenix database, the definitions of HF categories incorporate both LVSD andALVSD.

157 2.2 Cardio-Phoenix database

The prevalence of HF and associated ECG and ECHO findings in primary care can be estimated
 from the Cardio-Phoenix database, because the collected medical data was specifically from a
 patient population at risk of Cardiovascular Disease (CVD) including HF. Patients are adults with

an average age of 62.5, of which 51% are females, and have a minimum of three cardiovascular
risks or an existing cardiac condition.

163

164 In accordance with the guidance,³ risks for HF (any type) include hypertension, cardiovascular 165 disease, diabetes *mellitus*, obesity, known exposure to cardiotoxins, and family history of

- 166 cardiomyopathy (see Stage A at-risk for HF in ³). These risks were examined according to the 167 criteria of patients entered into the database.
- 167 crite 168
- 169 Databases consists of medical data from four clinical studies, completed at five European
- 170 clinical centers, between 2011 and 2019. The database contains the bio-signals including ECG
- and ECHO images, measurements, and findings for each patient. The echocardiographic
- assessment was typically performed immediately or soon after bio-signal recording, but not

173 more than a few days. There are some 24000 records with ~30sec length signals. The ground

174 truth of ECHO-findings (detailed in supplementary material) was established by cardiologist

175 consensus and confirmed with ECHO measurements. The ECG measurements and findings are

- 176 generated by state-of-the-art ECG algorithms based on a 12-lead ECG signal and confirmed by a
- 177 minimum of one, but up to four, cardiologists.
- 178

In the Cardio-Phoenix database, the HF categories are defined based on the above-mentioned
wider HF definitions, using all the available anamnesis/symptoms and clinical diagnoses
supported by ECG- and ECHO-findings:

- HFpEF: symptomatic HF with LVEF>50% and DD or LAE or LVH presence, extended with
 symptomatic AF, symptomatic PH, symptomatic AS or MS, symptomatic CAD or WMA.
 This definition of HFpEF is consistent with the *TOPCAT*, *RELAX*, and *ARIC* studies.⁴³
- HFmrEF: symptomatic HF with 40%<LVEF<50% extended with mild ALVSD confirmed
 with risk factors, HF scores, and co-morbidities of WMA or LAE, or LVH.
- HFrEF: symptomatic HF with LVEF<40% extended with ALVSD confirmed with risk factors, HF scores, and co-morbidities.
- 189

The overall database consists of 72.3% absent HF, 19.3% HFpEF, 5.9% HFmrEF and 2.5% HFrEF.
The 72.3% absent category includes normal patients and patients with non-HF CVD – typically
with a "mild" CVD condition. The overall HF patient is 27.7% in the database, and approximately
half of the HF patient has HFpEF type (HFpEF 69%, HFmrEF 21%, and HFrEF 10%) similar to
other studies.^{6,43}

195

196 This categorization was the basis of the data analysis presented in Table 1 and sections (3, 4, 197 and 5).

198

199 2.3 Study Limitation

The right side of the heart is less represented by the included ECHO-parameters and by ECG parameters even less, as such their place in the statistical results is limited.

202

Nonetheless, right-side heart failure and its structural, functional abnormalities and related
 pulmonary disease co-morbidities (Chronic obstructive pulmonary disease COPD) has attracted
 growing attention in the last few years. Right-heart side study through a bio-signal approach
 shows strong potential.

3 Prevalence statistics along four HF categories

209 **3.1 Method**

This work has been carried out in accordance with the Code of Ethics of the World Medical
 Association for experiments involving human subjects. Data used in the research were
 collection in a prior clinical study, already published with the Declaration of Helsinki state.⁴⁹
 To analyze prevalence along four HF categories a statistical analysis was performed on patient

214 groupings into a) All – all the patient records, b) Absent HF records, c) HFpEF records, d)

- 215 HFmrEF records and e) HFrEF records.
- 216

217 **3.2 Results**

Table 1 lists all the relevant information, measurements, and findings in the examined patient

- 219 population.
- 220

221 3.2.1 Highest prevalence

The listed measurements and findings show most of the abnormal mean values for the HFrEF category. Interestingly, the exceptions help us to better understand the HFpEF and HFmrEF categories:

- HFpEF shows the highest or significantly high value of Systolic Blood Pressure BP (it confirms other research, which shows HFpEF is prevalent in hypertensive populations⁵¹.), Interventricular Septal Diameter (IVSd), Relative Wall Thickness (RWT%), Aortic Valve Peak Velocity (AoV Vmax), AR Grade and Jet Area, Right Ventricular Systolic Pressure (RVSP), PQ and QT intervals, in addition, LVH, DDIM, AS, MS, AFib and Prolonged QT from findings. In addition, HFpEF shows the highest average age.
- HFmrEF shows the highest value of Diastolic BP, lowest T-wave axis, highest prevalence
 of Premature Atrial Contraction (PAC). In addition, significantly high prevalence of
 WMA, ST-T deviation, Myocardial Infarction (MI), and MS, which are closer to HFrEF
 values compared to HFpEF.
- Because of high variability and comorbidity rate, the HFrEF has the worst mean values
 and highest standard deviation for all the parameters, except for the parameters above
 mentioned. The distribution of several parameters confirms an earlier study result.³⁷
- 238
- 239 3.2.2 Characteristics of HFmrEF as a middle category

240 Until recently, the abnormalities that typically occur in HFmrEF compared to HFpEF and HFrEF 241 have not been as comprehensively investigated.

- 242 The presented analysis reveals that HFpEF do not so much differ from HFmrEF in prevalence
- and disease severity as by disease type. HFpEF mostly includes DD, LVH, and mild/moderate
- valve disease patients, whereas HFmrEF trends towards patients with ischemic problems:

WMA, MI, and ST-T deviation. Our analysis provides some relationships as presented in thesestatistics:

- LVH is represented within HFpEF and HFrEF but unexpectedly is a less typical indicator
 of HFmrEF
- DCM prevalence significantly increases in cases of HFmrEF from HFpEF and becomes
 frequent in HFrEF
- WMA is an important source of mildly reduced systolic function, with 8 times higher
 prevalence compared to patients with HFpEF. The additional prevalence increase is
 small compared to HFrEF.
- MI is typical in HFpEF, but even more so in patients with HFmrEF, where the prevalence is almost as high as in HFrEF, confirming a previous study.³⁷
- PAC is more typical in HFmrEF and Premature Ventricular Contraction (PVC) for HFrEF.
- 258 3.2.3 Typical abnormalities of three category
- 259 HFpEF group of patients are typically older, having hypertension, and obesity, where the typical
- 260 structural abnormality is the LVH, the typical function abnormality is the DD, the typical
- hemodynamical problem is any aortic/mitral valve disease or PH, and the typical
- 262 electrophysiological problem is AFib.
- 263 HFmrEF group of patients have similar comorbidities as HFpEF, but different types of problems:
- their typical structural abnormality is mild DCM, and the typical functional abnormality is WMA
- with either MI or ST-T deviation. The typical electrophysiological problems are AFib and PAC.
- Aortic valve disease is less typical compared to HFpEF, but Mitral/Tricuspid/Pulmonic aresimilar.
- 268 HFrEF group of patients have the highest levels of comorbidity and severity: the typical
- structural abnormalities are the DCM, left and right atrial and ventricular enlargement, the
- 270 typical functional abnormality is LVSD, and the typical hemodynamical problem is
- 271 Mitral/Tricuspid regurgitation and PH, and most common ECG abnormalities shows higher
- 272 prevalence including the ECG LVH and ECG RVH criteria. The exception are sinus bradycardia,
- 273 PAC, and prolonged QT.
- 274 Right-side heart abnormalities (RAE, RVE, RVH) show a significant increase in HFrEF categories.
- 275 The overall comorbidity ratio shows an increasing trend with the decreasing of systolic function
- and exacerbation of HF. However, RV dysfunction is highly prevalent in HFpEF as well,⁴⁴
- 277 moreover the recent COVID-19-related literature is increasingly referring to right side
- 278 dysfunction with HFpEF.^{45,46}
- 279
- 280 3.2.4 The summary of HF co-morbidities prevalence
- Table 2 shows the HF categories and typical co-morbidities in a summary analysis. The list of
- typical abnormalities or co-morbidities is listed using both the guideline and statistical analysis
- 283 based on the presented data.
- 284

285 3.2.5 ECG versus ECHO summary

- 286 To more clearly understand the differences between ECG and ECHO in predicting HF, we
- compare the Summary ECG with the Summary ECHO. In the database, both the ECG and ECHOinterpretations are extended with a summary finding, listed in Table 1:
- ECG summary classifies the ECG as normal, borderline or abnormal
- ECHO summary classifies the ECHO as Normal, Mild or Abnormal: both moderate or
- 291Severe, and where Mild means a minimum of one Mild finding, Abnormal means a292minimum of one Moderate/Severe finding
- 293 The best estimation reveals the limitation of ECG for HF: the ECG summary (Abnormal ECG)
- covers only 72.4% of HFpEF, 78.8% of HFmrEF, and 92.8% of HFrEF (average 81%), whereas the
- 295 ECHO summary (Abnormal ECHO) has higher percentages, 81.3% for HFpEF, 93.4% for HFmrEF
- and 100.0% for HFrEF (average 92%), shown in Table 1. In other words, ECHO is far more
- sensitive and less inconclusive for diagnosing HF compared to ECG.
- 298

300 4 Prevalence trend comorbidity statistics

This statistical analysis shows how the co-morbidity is continuously increasing in the function of
 deterioration in LV systolic function: transitions are demonstrated between the three HF
 categories. Etiology and comorbidity analysis helps to understand the phenotype of HF and
 confirms the diagnosis.⁴³

305

306 **4.1 Method**

307 In the presented analysis, consistent with the guidelines,¹, LVEF is used as an independent

variable to estimate the prevalence of ECG and ECHO abnormalities. LVEF is the key continual
 measurement that separates the three categories of HF, which is split into 9 sub-categories

310 with center values here, see in Fig. 1. Patients were grouped along these sub-categories and the

311 prevalence of ECHO and ECG findings were calculated.

312 **4.2 Results**

The results are plotted in Fig. 1 together with the average value of some principal ECHO and ECG measurements:

- 315 Graph A) shows a deteriorating trend of all the key ECG- and ECHO-measurements as a 316 function of LVEF. Left Atrial Volume Index (LAVI) from ECHO and Heart Rate Variability (HRV) from ECG has the largest relative change, however HRV having maximum at 317 LVEF=42%. Obesity, measured by average BMI, shows a slight increasing trend, and the 318 319 percentage of Female patients drastically decreases with decreasing LVEF. This confirms 320 that the HFpEF patient is biased to females, and the HFrEF patient biased to males. It is 321 widely accepted that heart disease progresses with age, and the cardiac comorbidity 322 statistics confirm both the disease progression and the increased comorbidity factor 323 with increasing age.
- Graph B) shows constant increasing prevalence of almost all ECHO-findings, except:
 Impaired Relaxation (DDIM) having maximum around LVEF=57%; Aortic Stenosis (AS)
 and Mitral Stenosis (MS) having maximum around LVEF=42%. This confirms DDIM and
 aortic-mitral stenosis patients belong mostly to the HFpEF and HFmrEF categories.
- Graph C) shows constant increasing prevalence of almost all ECG-findings, except: S.
 Bradycardia has maximum around LVEF=57%; Sinus Tachycardia has minimum at
 LVEF=52%, ST-T deviation maximum around LVEF=42%; Rightward Axis having minimum
 at LVEF=57% and maximum at LVEF=42%. This confirms that typically, the HF patient has
 LVH with leftward axis, the Rightward Axis decreasing, but the typical right-side disease
 patients belong to HFrEF, that is why it is increasing again at the LVEF<45% groups.
- Graph D) shows the prevalence of each of the discussed HF categories, primarily
 separated based on LVEF. The maximum prevalence of HFpEF is around LVEF=52%,
 below 50% HFmrEF replaces the HFpEF classification and below 40% HFrEF replaces the
 HFmrEF classification.

339 5 PCA comorbidity statistics

340 **5.1 Method**

341 A Principal Component Analysis (PCA) was completed to reveal and unravel patterns of comorbidities, i.e. group of comorbidities associated with each other.⁴⁷ PCA is a data reduction 342 method that transforms the original set of variables into a smaller set of Principal Components 343 344 (PCs), which are linear combinations of the original variables. PCs retain as much of the 345 variability in the data set as possible, with the first component retaining the greatest amount of 346 the variation present and the other components progressively retaining a decreasing amount of 347 variation.48 348 349 In this PCA the largest variance is discovered in the data of the most important ECG, ECHO and 350 patient body size measurements, which helps us to understand the interactions or comorbidities of common cardiovascular diseases. Data was extended with two HFpEF scores: the 351 *HFA-PEFF* score 4 , and the H_2FPEF score 9 , in order to enable the determination whether the HF 352 353 coincides with the direction of overall comorbidity rate. 354 355 Table 4 in supplementary material lists the 42 parameters included in PCA and the associated 356 CVD.

357

358 **5.2 Results**

359 Fig. 3 shows the scatter plot of HF categories in function of *PCA1* and *PCA2*: the left graph A.) shows the four HF categories, where the centers are marked with black squares and numbers; 360 361 the right graph B) shows the body size categories according to CHART Body Size Index (CBSI), where the CBSI<2.2 represent the smaller body size, 2.2<CBSI<2.4 represent the middle body 362 363 size, and CBSI>2.4 represent the bigger body size (for more details about why CBSI is used 364 instead of BSI can be seen in supplementary material). PCA1 parameter is a good indication for 365 HF with significant difference between Absent HF and HFpEF, and between HFpEF and HFrEF. 366 There is no significant difference in *PCA1* between the two mild HF categories, HFpEF and 367 HFmrEF.

368

The second component *PCA2* represents the body size, which has not a pathological direction as *PCA1*. *PCA2* is at an independent perpendicular direction to *PCA1*, which carries the second biggest variance of data.

372

373 The scatter plot of the three heart rate (HR) categories - separated by average HR parameters -

- in function PCA1 and PCA3, shown in graph C), and the Heart Rate Variability (HRV) categories –
- 375 separated by standard deviation of RR intervals (RRstd) parameters in function of PCA1 and
- 376 PCA4 (graph D.). The PCA1 seems independent from HR but dependent from HRV. PCA3
- 377 represents the HR value, and *PCA4* the HRV values. The scatter plot of four HF categories in

- function *PCA1* and *PCA5* shown in graph E). *PCA5* shows a DD related pathological direction,
- 379 therefore is slightly higher separator between HFpEF and HFmrEF.
- For more details about the presented PCs see Fig. 4 in supp. material, which shows the PCA
- 381 coefficients of the first five components.
- 382

383 5.2.1 Principal Components

Each of the PCs point in a specific direction, determined or represented by input parameters identified in Fig. 2. The presented first five PCA are considered the most important dimensions in the 42-dimension space. These first five PCA's cover half of all the variance provided by the 42 dimensions: 18.2%, 11%, 9%, 5.6% and 4.8%, with the summary 49%.

- 388
- 389 Most of the common heart diseases have strong comorbidity, since all take part in the PCA1: HF
- and LVSD, atrial and ventricular enlargements, PH, MR, TR and LVH. The different natures of
- 391 HFpEF and HFmrEF were not involved by the presented principal components. However, the
- 392 LVEF can separate these two categories, see in graph F) in Fig 2., which shows the three types of
- 393 HF in 2D space of PCA1 and LVEF parameter.
- 394

The big role of *PCA1* can be observed in graph F), where *PCA1* distinguishes HFpEF from HF absent patients, which is not distinguishable by LVEF. LVEF can only distinguish HFmrEF and HFrEF from patients with LVEF>50%. Medical information incorporated in *PCA1* is required to

- 398 make differential diagnosis of HFpEF.
- 399

400 The *PCA2*, 3 and 4 can be considered as independent components from *PCA1* and from each-401 other. These fulfill the supplementary directions: *PCA2* - body size, *PCA3* - HR and *PCA4* -

- 402 arrhythmias.
- 403

The *PCA2* result confirms the important need of data normalization (for ECHO and ECG
measurements) by body size or, at the very least, by gender. However, body size is best
represented by BSA or CBSI because it relates more to the individual compared to the binary
gender.

408

The *PCA5* is a supplementary diagnostic component for HF that helps to distinguish categories

- 410 of DD and categories of HF. Compared to *PCA1, PCA5* shows higher distance between HFpEF
- and HFmrEF, as it represents the co-morbidity aspect of DD that is characteristic of HFpEF,
- 412 despite the fact that in nearly half of the cases DD is absent $5^{,}$.
- 413

414 5.2.2 ECG and ECHO factors of PCA1

415 The covariance pattern of ECG- and ECHO-measurements representing cardiac function was

- 416 investigated by the PCA. The first principal component (*PCA1*) is interpreted as the overall
- 417 comorbidity degree. The PCA established that the *PCA1* is representative of **structural**
- 418 **abnormalities:** the atrial and ventricular enlargements. The direction of this component is

- 419 mostly suitable to the HF severity categories: the HFpEF diagnostic scores are the most
- 420 important participants in *PCA1*. This confirms the importance of ECHO over ECG in HF
- diagnoses, since these scores rely mainly on key ECHO-measurements: E/e', LVMI, LAVI and
- 422 RVSP.
- 423
- 424 The LAE defined by LAVI is the most representative ECHO-finding in the overall comorbidity
- 425 rate, which coincides with the probability direction of HF. However, no single ECHO-
- 426 measurement is suitable to identify all HF patients, hence the reason for the use of HF score
- 427 approaches, where a set of relevant ECHO-findings are aggregated in order to account for the
- 428 varying nature of HF. For example, ECG algorithms predicting LVEF<35%, like ^{24,25}, target only
- 429 HFrEF category, as such they are inherently insensitive for the larger group of HF patients found
- 430 in primary care (HFmrEF and HFpEF).
- 431
- 432 In *PCA1*, the second group of coefficients are related to the **functional abnormalities**.
- Astonishingly, LVEF is the 14th input parameter according to the coefficient's values, having
- 434 similar impact as age, arrhythmia, prolonged PR, RVSP and Mitral/Tricuspid regurgitation. This
- 435 means LVEF, age, arrhythmia, PR interval and valve diseases are less representative of the
- 436 overall comorbidity compared to aggregated diagnostic scores and chamber enlargements.

438 6 Discussion

439 6.1 A novel Diagnosis, "Consider HF" for primary care

440 Unlike ECG, bio-signal derived ECHO-findings processed through a purpose designed AI system,
441 can predict the structural and functional abnormalities and measurements, consistent with

table 2 above, essential to the detection accuracy for HF.⁴⁹ including low LVEF.

- 443
- 444 The real importance of bio-signal derived ECHO-findings lies in its simplicity as it makes
- detection of HF more immediate on patient presentation to Primary Care, precluding the use of
- 446 purely symptomatic based clinical diagnosis that delays access to treatment. This means that on
- 447 initial patient presentation to Primary Care, clinicians will be able to recognize HF, including
- 448 classifying its severity and category, especially when symptoms remain inconclusive,
- 449 confounding or ambiguous.
- 450
- 451 Cardio-HART[™] system uses novel bio-signals analyzed by Artificial Intelligence, can predict 14 of
- 452 the most prevalent and important ECHO-findings^{26,} to support the novel diagnostic indications
- 453 called "Consider HF"¹. CHART is intended to: *"detect potential abnormalities of a structural*
- 454 and functional nature related to a specific HF phenotype, independently from the current
- 455 *patient symptoms."* Where patient symptoms can be inconclusive, confounding and or
- 456 ambiguous, Cardio-HART provides Echo finding based indications of cardiac abnormalities,
- 457 including LVEF, consistent with this research such that a HF diagnosis should be considered.
- 458
- 459 The primary criteria of "consider HF" follows the LVEF categories as per the latest guideline ¹,
- 460 while the secondary criteria confirm LVEF with the co-morbidities explored in this research and
- their risk factors including asymptomatic patients (ALVSD). Table 3 lists the supporting ECG and
- 462 ECHO-findings provided by CHART to aid the "consider HF" determination.
- 463

6.2 Verification by HFA algorithm

The accuracy of the "consider HF" categorization of HF is verified using the likelihood-based
adaptations of HFA algorithm. The HF score-based algorithm relies mainly on echocardiographic
measurements, and it is necessary because no single measurement is sufficiently decisive, but
the HF probability can be well represented by aggregating the individual measurements ^{4,9.}

¹ © 2021 Cardio Phoenix Inc., "consider HF" is also a trademark of Cardio-Phoenix Inc.

- 470 Fig. 3 shows the three "consider HF" categories plus the "Absent HF" category in function of
- 471 LVEF (vertical axis) and the two likelihood-based scores (horizontal axis): A) the H2FPEF Score;
- B) the *HFA-PEFF* Score. Both HF score adaptations are calculated using sigmoid probability
- 473 function instead of strict binary threshold in order to ensure higher resolution and to better
- 474 resolve borderline cases.
- 475
- 476 The two scores have similar results: The HFmrEF and HFrEF categories are primarily confirmed
- 477 by LVEF, but the two HF scores also show non-normal ranges, similarly for HFpEF categories.
- 478 The score results demonstrate the need of a second and independent component from LVEF,
- 479 which can separate the HFpEF from the Absent HF category. This HFpEF component can be
- represented either by of the mentioned scores, but only in cases where ECHO is available, or, in
- 481 cases where ECHO is not available, by the bio-signal predicted ECG/ECHO structural and
- 482 functional parameters, as produced by CHART.
- 483

484 6.3 Conclusions

The prevalence-based comorbidity analysis shows that the discussed ECHO-findings are strong
 indicators for HF and its category. More precisely, for HF, ECHO shows enlarged heart with
 decreased myocardial contractility and general abnormal heart functioning.

488

Key set of ECHO-findings are sufficiently representative of HF when taken together as opposed to a single measurement, like LVEF. The two HF score techniques discussed in this study (*HFA-PEFF*^{4,} and *H2FPEF*^{9,}) confirms this approach, as they rely on Echo-finding indicators for the critical components of their score, precisely to avoid reliance on LVEF. The use of LVEF only would lead to a limited HF prediction capability focusing only on the HFrEF category, ignoring

- 494 HFpEF altogether and much of HFmrEF, resulting in a high incidence of false negative.
- 495

496 As Echocardiography is not widely or easily available in primary care, the key structural

- 497 (chamber enlargements) and **functiona**l abnormalities related measurements are not available
- 498 precluding the ability to diagnose HF other than through mainly symptomatic means. The
- 499 standard ECG findings do not provide acceptable diagnostic power for HF, less so for its
- 500 categorization.
- 501

502 As more patients with HF are expected to be living longer than ever before, healthcare

- priorities will increasingly shift to managing HF co-morbidities ⁵⁰. A bio-signal based system,
- indicated for use in Primary Care, can address the lack of a suitable device. In such a bio-signal
- 505 based approach the classifying of a set of ECHO-findings by AI is recommended, conformant
- with the 2021 guidelines set by the ESC for diagnosing of HF. In primary care the use of novel
- 507 bio-signals of a physiological nature such as those found in Cardio-HART[™] can provide a better
- 508 understanding of the structural and functional abnormalities and thereby increase HF detection
- 509 accuracy for all 3 types of HF, even in asymptomatic patients.
- 510

- 511 Further research is warranted to investigate in more detail the relationship between HF
- 512 categories and right-side HF through the window of bio-signals, risk factors, detectable
- 513 abnormalities, COPD and other co-morbidities and symptoms.

514 7 Source of funding

- 515 The collection of the data used in this paper was previously collected in prior clinical studies
- 516 funded in part by UVA Research Inc., no other funding was involved.

517 **7.1 Authors Contributions**

- 518 "G.B.Z. designed the analysis; E.SZ. and A.B.SZ. collected the data; G.K. validated the data; N.C.
- and D.T. contributed analysis tools; I.K. performed the analysis; A.Z. and M.A.N. wrote thepaper."

521 **7.2 Conflict of interests**

- 522 The following relationship to industry disclosed:
- Giuseppe Biondi Zoccai: consulted for Cardionovum, CrannMed, InnovHeart, Meditrial,
 Opsens Medical, and Replycare.
- Istvan Kecskes: Director in UVA research corp., and works in project at Cardio-Phoenix
 Inc.
- 527
- 528

529 8 References

- [1] McDonagh, T. A., Metra, M., Adamo, M., et al. "2021 ESC Guidelines for the diagnosis
 and treatment of acute and chronic heart failure: Developed by the Task Force for the
 diagnosis and treatment of acute and chronic heart failure of the European Society of
 Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of
 the ESC." *European heart journal* 42.36 (2021): 3599-3726.
- 535 [2] Andronic, Anca Andreea, Sorina Mihaila, and Mircea Cinteza. "Heart failure with mid 536 range ejection fraction—a new category of heart failure or still a gray
 537 zone." *Maedica* 11.4 (2016): 320.
- [3] Bozkurt, B., Coats, A. J., Tsutsui, H., et al. "Universal Definition and Classification of
 Heart Failure: A Report of the Heart Failure Society of America, Heart Failure Association
 of the European Society of Cardiology, Japanese Heart Failure Society and Writing
 Committee of the Universal Definition of Heart Failure." *Journal of cardiac failure* (2021).
- [4] Pieske, B., Tschöpe, C., De Boer, R. A., et al. "How to diagnose heart failure with
 preserved ejection fraction: the HFA–PEFF diagnostic algorithm: a consensus
 recommendation from the Heart Failure Association (HFA) of the European Society of
 Cardiology (ESC)." *European heart journal* 40.40 (2019): 3297-3317.
- 547 [5] Afsin Oktay, A., and Sanjiv J Shah. "Diagnosis and management of heart failure with
 548 preserved ejection fraction: 10 key lessons." *Current cardiology reviews* 11.1 (2015): 42549 52.
- [6] Lam, C. S., Donal, E., Kraigher-Krainer, E., et al.. Epidemiology and clinical course of
 heart failure with preserved ejection fraction. *Eur J Heart Fail* 2011; 13: 18-28.
- 552[7] Gazewood, John D., and Patrick L. Turner. "Heart failure with preserved ejection553fraction: diagnosis and management." American family physician 96.9 (2017): 582-588.
- 554 [8] Simmonds, S. J., Cuijpers, I., Heymans, S., et al. "Cellular and molecular differences
 555 between HFpEF and HFrEF: a step ahead in an improved pathological
 556 understanding." *Cells* 9.1 (2020): 242.
- [9] Reddy, Y. N., Carter, R. E., Obokata, M., et al. "A simple, evidence-based approach to
 help guide diagnosis of heart failure with preserved ejection fraction." *Circulation* 138.9
 (2018): 861-870.
- 560 [10] Kraigher-Krainer, E., Shah, A. M., Gupta, D. K., et al. "Impaired systolic function
 561 by strain imaging in heart failure with preserved ejection fraction." *Journal of the* 562 American College of Cardiology 63.5 (2014): 447-456.
- 563 [11] Bshiebish, Hasanain Ali Hameed, Ali Hussein Al-Musawi, and Safaa Ali Khudeir.
 564 "Role of global longitudinal strain in assessment of left ventricular systolic function in
 565 patients with heart failure with preserved ejection fraction." *Journal of the Saudi Heart*566 Association 31.2 (2019): 100-105.
- 567 [12] Sahlen, Anders, and Reidar Winter. "How should we measure global and
 568 regional left ventricular systolic function?." *Journal of echocardiography* 9.2 (2011): 41 569 50.

570 Velagaleti, R. S., Gona, P., Pencina, M. J., et al. "Left ventricular hypertrophy [13] 571 patterns and incidence of heart failure with preserved versus reduced ejection fraction." 572 The American journal of cardiology 113.1 (2014): 117-122. 573 [14] Lee, D.S.; Gona, P.; Vasan, R.S.; Larson, M.G.; Benjamin, E.J.; Wang, T.J.; Tu, 574 J.V.; Levy, D. Relation of disease pathogenesis and risk factors to heart failure with 575 preserved or reduced ejection fraction: Insights from the framingham heart study of the 576 national heart, lung, and blood institute. *Circulation* 2009, 119, 3070–3077. 577 Lüscher, Thomas F. "Heart failure subgroups: HFrEF, HFmrEF, and HFpEF with or [15] without mitral regurgitation." European Heart Journal 39.1 (2018): 1-4. 578 Hussain, N., Charalampopoulos, A., Ramjug, et al. "Pulmonary hypertension in 579 [16] 580 patients with heart failure and preserved ejection fraction: differential diagnosis and 581 management." Pulmonary circulation 6.1 (2016): 3-14. 582 [17] Kjaergaard, J., Akkan, D., Iversen, K. K., et al. "Prognostic importance of pulmonary hypertension in patients with heart failure." The American journal of 583 cardiology 99.8 (2007): 1146-1150. 584 585 Schröder, J., Nuding, S., Müller-Werdan, U., Werdan, K., Kluttig, A., Russ, M., ... [18] 586 & Medenwald, D. (2015). Performance of Sokolow-Lyon index in detection of 587 echocardiographically diagnosed left ventricular hypertrophy in a normal Eastern 588 German population-results of the CARLA study. BMC cardiovascular disorders, 15(1), 1-589 7. 590 Burgos, P. F. M., Luna, B., Costa, F. D. A., Bombig, M. T. N., Souza, D. D., Bianco, [19] 591 H. T., ... & Póvoa, R. (2016). Electrocardiogram performance in the diagnosis of left 592 ventricular hypertrophy in hypertensive patients with left bundle branch block. Arquivos 593 brasileiros de cardiologia, 108, 47-52. 594 [20] Erdei T, Rodrigues J, McIntyre B, et al. 8 Diagnostic performance of ECG 595 detection of left atrial enlargement in patients with arterial hypertension relative to the 596 cardiac magnetic resonance gold-standard: Impact of obesity. Heart 2016;102:A6-A7. 597 Tsao, C. W., Josephson, M. E., Hauser, T. H., O'Halloran, T. D., Agarwal, A., [21] 598 Manning, W. J., & Yeon, S. B. (2008). Accuracy of electrocardiographic criteria for atrial 599 enlargement: validation with cardiovascular magnetic resonance. Journal of 600 Cardiovascular Magnetic Resonance, 10(1), 1-7. 601 Kelly, James, & Kelleher, Kevin (2000). The electrocardiogram in heart failure. [22] 602 Age and ageing, 29(3), 203-206. 603 Cincin, A., Ozben, B., & Erdogan, O. (2012). Diagnostic utility of specific [23] 604 electrocardiographical parameters in predicting left ventricular function. Experimental & 605 Clinical Cardiology, 17(4), 210. 606 Attia, Z. I., Kapa, S., Lopez-Jimenez, F., et al. "Screening for cardiac contractile [24] 607 dysfunction using an artificial intelligence-enabled electrocardiogram." Nature medicine 608 25.1 (2019): 70-74. 609 Alhamaydeh, M., Gregg, R., Ahmad, A., et al. "Identifying the most important [25] 610 ECG predictors of reduced ejection fraction in patients with suspected acute coronary 611 syndrome." Journal of electrocardiology 61 (2020): 81-85. 612 Cardio-HART[™] - a Breakthrough Cardiac-Telemedicine[™] device, now CE-Marked. [26] 613 (2021). Retrieved 20 December 2021, from

| 614 | https://www.cardiophoenix.com/news/cardio-hart-a-breakthrough-cardiac- |
|-----|--|
| 615 | <u>telemedicine-device-now-ce-marked</u> |
| 616 | [27] Shah, S. J., Katz, D. H., & Deo, R. C. (2014). Phenotypic spectrum of heart failure |
| 617 | with preserved ejection fraction. <i>Heart failure clinics</i> , 10(3), 407-418. |
| 618 | [28] Movahed, Mohammad Reza, and Yuji Saito. "Obesity is associated with left |
| 619 | atrial enlargement, E/A reversal and left ventricular hypertrophy." Experimental & |
| 620 | Clinical Cardiology 13.2 (2008): 89. |
| 621 | [29] Aouar, L. M. M. E., Meyerfreud, D., Magalhães, P., et al. "Relationship between |
| 622 | left atrial volume and diastolic dysfunction in 500 Brazilian patients." Arquivos |
| 623 | brasileiros de cardiologia 101.1 (2013): 52. |
| 624 | [30] Prasad A, Hastings JL, Shibata S, et al. Characterization of static and dynamic left |
| 625 | ventricular diastolic function in patients with heart failure with a preserved ejection |
| 626 | fraction. Circ Heart Fail 2010; 3: 617-26. |
| 627 | [31] McCrohon, J. A., Moon, J. C. C., Prasad, S. K., et al. "Differentiation of heart |
| 628 | failure related to dilated cardiomyopathy and coronary artery disease using gadolinium- |
| 629 | enhanced cardiovascular magnetic resonance." <i>Circulation</i> 108.1 (2003): 54-59. |
| 630 | [32] van Gils, L., Clavel, M. A., Vollema, E. M., et al. "Prognostic implications of |
| 631 | moderate aortic stenosis in patients with left ventricular systolic dysfunction." Journal of |
| 632 | the American College of Cardiology 69.19 (2017): 2383-2392. |
| 633 | [33] Chaliki, H. P., Mohty, D., Avierinos, J. F., et al. "Outcomes after aortic valve |
| 634 | replacement in patients with severe aortic regurgitation and markedly reduced left |
| 635 | ventricular function." <i>Circulation</i> 106.21 (2002): 2687-2693. |
| 636 | [34] Mutlak, D., Lessick, J., Khalil, S., Yalonetsky, et al. "Tricuspid regurgitation in |
| 637 | acute heart failure: is there any incremental risk?." European Heart Journal- |
| 638 | Cardiovascular Imaging 19.9 (2018): 993-1001. |
| 639 | [35] Delepaul, B., Robin, G., Delmas, et al. "Who are patients classified within the |
| 640 | new terminology of heart failure from the 2016 ESC guidelines?." ESC heart failure 4.2 |
| 641 | (2017): 99-104. |
| 642 | [36] Carson, P., Johnson, G., Fletcher, R., et al. "Mild systolic dysfunction in heart |
| 643 | failure (left ventricular ejection fraction> 35%): baseline characteristics, prognosis and |
| 644 | response to therapy in the Vasodilator in Heart Failure Trials (V-HeFT)." Journal of the |
| 645 | American College of Cardiology 27.3 (1996): 642-649. |
| 646 | [37] Webb, J., Draper, J., Fovargue, L., et al. "Is heart failure with mid range ejection |
| 647 | fraction (HFmrEF) a distinct clinical entity or an overlap group?." IJC heart & vasculature |
| 648 | 21 (2018): 1-6. |
| 649 | [38] Karaye, Kamilu M., and Mahmoud U. Sani. "Electrocardiographic abnormalities |
| 650 | in patients with heart failure." Cardiovascular journal of Africa 19.1 (2008): 22. |
| 651 | [39] Anter, Elad, Mariell Jessup, and David J. Callans. "Atrial fibrillation and heart |
| 652 | failure: treatment considerations for a dual epidemic." <i>Circulation</i> 119.18 (2009): 2516- |
| 653 | 2525. |
| 654 | [40] Gori, M., Redfield, M. M., Calabrese, A., et al. "Is mild asymptomatic left |
| 655 | ventricular systolic dysfunction always predictive of adverse events in high-risk |
| 656 | populations? Insights from the DAVID-Berg study." <i>European journal of heart failure</i> |
| 657 | 20.11 (2018): 1540-1548. |

- Heart Failure Society of America. "Section 5: Management of Asymptomatic
 Patients With Reduced Left Ventricular Ejection Fraction." *Journal of cardiac failure* 12.1
 (2006): e26-e28.
- 661 [42] Wang, T. J., Evans, J. C., Benjamin, E. J., et al. "Natural history of asymptomatic
 662 left ventricular systolic dysfunction in the community." *Circulation* 108.8 (2003): 977663 982.
- Parcha, V., Malla, G., Kalra, R., et al. "Diagnostic And Prognostic Implications of
 Heart Failure With Preserved Ejection Fraction Scoring Systems." *Journal of Cardiac Failure* 26.10 (2020): S38.
- 667 [44] Gorter, T. M., van Veldhuisen, D. J., Bauersachs, J., et al. "Right heart
 668 dysfunction and failure in heart failure with preserved ejection fraction: mechanisms
 669 and management. Position statement on behalf of the Heart Failure Association of the
 670 European Society of Cardiology." *European journal of heart failure* 20.1 (2018): 16-37.
- [45] Lan, Yonghao, Wei Liu, and Yujie Zhou. "Right Ventricular Damage in COVID-19:
 Association Between Myocardial Injury and COVID-19." *Frontiers in Cardiovascular Medicine* 8 (2021): 82.
- 674 [46] **Mehra, Mandeep R., and Frank Ruschitzka.** "COVID-19 illness and heart failure: 675 a missing link?." *JACC Heart Fail*. 2020 Jun;8(6):512-514.
- 676 [47] Gorter, T. M., van Veldhuisen, D. J., Bauersachs, J., et al. "Patterns of co677 occurring comorbidities in people living with HIV." Open forum infectious diseases. Vol.
 678 5. No. 11. US: Oxford University Press, 2018.
- 679 [48] Jolliffe I. Principal Component Analysis. New York: Wiley Online Library; 2002.
- 680 [49] Calcagno, S., Biondi Zoccai, G., Stankovic, et al. (2021) Novel Tech throws knock 681 out punch to ECG improving GP referral decisions to cardiology. *Open heart*, 9(1),
 682 e001852.
- 683 [50] **Groenewegen, A., Rutten, F. H., Mosterd, A.,** et al. "Epidemiology of heart 684 failure." *European journal of heart failure* 22.8 (2020): 1342-1356.
- [51] Saba, P. S., Cameli, M., Casalnuovo, G., Ciccone, M. M., et al. Ventricular–
 vascular coupling in hypertension: methodological considerations and clinical
 implications. *Journal of cardiovascular medicine*, 15(11), (2014): 773-787.

689 9 Figure legends

690 Figure 1 – Comorbidity analysis in function of LVEF categories (in descending order): A) Average measurements:

691 ECHO, ECG, BMI, Female, Age, B) ECHO-finding prevalence, C) ECG-finding prevalence, D) HF categories

692 prevalence (Abbreviations: AR, Aortic Regurgitation; AS, Aortic Stenosis; BMI, body mass index; DCM, Dilated

693 Cardiomyopathy; DDIM, Impaired Relaxation of Diastolic Dysfunction; ECG, Electrocardiogram; ECHO,

694 Echocardiogram; HF, Heart Failure; HFmrEF, Heart Failure with mildly reduced LVEF; HFpEF, Heart Failure with

preserved LVEF; HFrEF, Heart Failure with reduced LVEF; HRV, Heart Rate Variability; LAE, Left Atrial Enlargement;

LAVI, Left Atrial Volume Index; LVEF%, Left Ventricular Ejection Fraction (Teichholz); LVH, Left Ventricular
 Hypertrophy; LVIDd, End-diastolic Left Ventricular Diameter; LVMI, Left Ventricular Mass Index; LVSD, Left

Hypertrophy; LVIDd, End-diastolic Left Ventricular Diameter; LVMI, Left Ventricular Mass Index; LVSD, Left
 Ventricular Systolic Dysfunction; MR, Mitral Regurgitation; MS, Mitral Stenosis; MV E/A, E/A Wave Velocity; PH,

699 Pulmonary Hypertension; QTc, Corrected QT interval; RAE, Right Atrial Enlargement; RVE, Right Ventricular

Financial and generative constraints of the second of the s

701 Regurgitation; WMA, Wall Motion Abnormality)

Figure 2 – 2D scatter plot of (A) HF categories in function of PCA1 and PCA2, (B) body size categories in

function of PCA1 and PCA2, (C) HR categories in function PCA3 and PCA1, (D) HRV categories in function of

PCA4 and PCA1, (E) HF categories in function of PCA5 and PCA1, (F) Four HF categories in function of LVEF

and PCA1 (Abbreviations: BSI, body size index; CBSI – CHART body size index (similar to body surface area); HF,

706 Heart Failure; HFmrEF, Heart Failure with mildly reduced LVEF; HFpEF, Heart Failure with preserved LVEF;

707 HFrEF, Heart Failure with reduced LVEF; HR, Heart Rate; HRV, Heart Rate Variability; LVEF, Left Ventricular

Figure 10 Example 10

710 Standard Deviation of RR intervals)

711 Figure 3 – Scatter plot of HF categories in function LVEF (vertical) and HF scores (horizontal) (Abbreviations:

712 HFmrEF, Heart Failure with mildly reduced LVEF; HFpEF, Heart Failure with preserved LVEF; HFrEF, Heart Failure

713 with reduced LVEF; LVEF, Left Ventricular Ejection Fraction (Teichholz))

Table 1 – Distribution statistics of ECHO and ECG interpretation in Cardio Phoenix Database along the four HF category – In each row, the worst or most abnormal (typically the maximum, but in some cases the minimum) values are highlighted with bold text, similarly, the highest standard deviation is also highlighted, which denotes the highest variability.

| | HF category | | A | | Absen | t HF | HFp | EF | HFmr | EF | HFri | <u>5</u> F |
|--------------------------|-----------------------|-------------------|-------|------|-------|------|-------|------|-------|------|-------|------------|
| Group | Field | Unit | М | STD |
| | Age | year | 62.6 | 13.8 | 59.7 | 13.8 | 72.0 | 9.4 | 67.9 | 10.3 | 67.2 | 12.1 |
| | Female | % | 50.8 | 0.5 | 53.8 | 0.5 | 48.0 | 0.5 | 35.5 | 0.5 | 20.0 | 0.4 |
| | BMI | kg/m² | 27.9 | 5.2 | 27.6 | 5.2 | 28.5 | 5.3 | 28.8 | 5.2 | 29.2 | 6.6 |
| General and Body Size | BSA | m ² | 1.9 | 0.2 | 1.9 | 0.2 | 1.9 | 0.2 | 1.9 | 0.2 | 2.0 | 0.3 |
| | Height | cm | 167.5 | 9.1 | 167.7 | 9.2 | 166.2 | 8.7 | 167.7 | 8.7 | 169.4 | 9.9 |
| | Weight | kg | 78.3 | 16.7 | 77.7 | 16.4 | 79.1 | 16.8 | 81.3 | 16.6 | 84.3 | 21.7 |
| | Systolic BP | mmHg | 127.8 | 13.3 | 127.4 | 13.2 | 129.6 | 13.7 | 128.2 | 13.2 | 125.2 | 14.3 |
| | Diastolic BP | mmHg | 78.6 | 9.9 | 78.8 | 9.6 | 77.8 | 9.7 | 78.9 | 12.9 | 77.4 | 11.6 |
| | HR | bpm | 70.0 | 13.6 | 68.4 | 11.8 | 73.7 | 16.8 | 76.3 | 17.7 | 77.8 | 15.8 |
| | RR std | ms | 59.2 | 61.8 | 46.3 | 44.9 | 96.2 | 85.0 | 85.6 | 76.0 | 117.1 | 94.0 |
| | LF/HF (0.15Hz) | ms | 1.6 | 0.9 | 1.8 | 0.9 | 1.3 | 0.8 | 1.2 | 0.8 | 1.1 | 0.6 |
| | QRS axis | deg | 25.1 | 39.8 | 28.8 | 36.2 | 16.8 | 45.9 | 11.3 | 45.5 | 4.6 | 54.1 |
| | PQ interval | ms | 181.8 | 37.7 | 175.2 | 28.6 | 201.7 | 51.1 | 195.7 | 52.4 | 204.7 | 52.7 |
| | P interval | ms | 117.5 | 18.4 | 118.2 | 14.5 | 115.4 | 26.3 | 114.2 | 26.3 | 118.0 | 29.1 |
| ECG | P terminal force | mVms | 3.0 | 2.7 | 3.1 | 2.5 | 2.4 | 2.8 | 2.8 | 3.2 | 3.1 | 3.9 |
| measurements | QT interval | ms | 408.6 | 37.5 | 407.8 | 34.4 | 412.2 | 44.7 | 406.6 | 46.0 | 411.4 | 44.3 |
| | QTc (Framingham) | ms+ | 425.1 | 26.0 | 422.1 | 23.3 | 433.0 | 30.1 | 432.3 | 31.1 | 440.7 | 33.9 |
| | QRS interval | ms | 92.3 | 21.1 | 89.2 | 17.8 | 98.8 | 24.9 | 102.5 | 25.5 | 115.4 | 32.6 |
| | VAT (Rwave peak time) | ms | 43.1 | 11.4 | 41.4 | 9.4 | 46.6 | 14.3 | 49.2 | 13.3 | 53.9 | 17.8 |
| | Taxis | deg | 33.2 | 49.5 | 35.9 | 39.7 | 27.1 | 65.3 | 20.0 | 74.0 | 27.8 | 86.7 |
| | Rsum (V1:V6) | uV | 4282 | 2138 | 4387 | 2091 | 4093 | 2248 | 3997 | 2165 | 3187 | 2204 |
| | LVH Score | score | 166 | 201 | 128 | 159 | 256 | 242 | 320 | 293 | 353 | 264 |
| | IVSd | mm | 10.2 | 1.8 | 10.0 | 1.6 | 11.2 | 2.0 | 10.4 | 1.9 | 10.0 | 2.1 |
| | LVIDd | mm | 51.6 | 6.8 | 50.0 | 5.4 | 53.6 | 6.7 | 58.7 | 8.4 | 65.1 | 9.8 |
| | LVIDs | mm | 33.8 | 6.8 | 31.9 | 4.7 | 35.3 | 5.8 | 44.4 | 6.4 | 53.1 | 8.7 |
| | LVEF (Teichholz) | % | 63.3 | 8.7 | 65.5 | 6.5 | 62.5 | 6.8 | 47.6 | 2.4 | 37.5 | 4.6 |
| | RWT | % | 34.4 | 6.7 | 34.7 | 6.3 | 35.5 | 7.3 | 31.4 | 7.3 | 27.2 | 8.4 |
| | LVmass | g | 187.8 | 62.0 | 172.7 | 49.3 | 221.7 | 66.5 | 240.9 | 79.4 | 270.0 | 86.6 |
| | LVMI (LVmass/BSA) | g/m ² | 98.8 | 30.8 | 91.0 | 23.5 | 117.0 | 34.1 | 124.9 | 41.1 | 138.0 | 45.8 |
| | LAV | mL | 36.6 | 20.8 | 29.9 | 11.1 | 51.9 | 25.0 | 58.4 | 33.7 | 74.5 | 31.4 |
| | LAVI (LAV / BSA) | mL/m ² | 19.3 | 11.1 | 15.8 | 5.6 | 27.4 | 13.2 | 30.7 | 19.4 | 38.5 | 18.5 |
| | RAV | mL | 40.1 | 25.0 | 34.0 | 14.2 | 54.5 | 35.3 | 58.1 | 39.7 | 78.5 | 40.2 |
| | RAVI (RAV / BSA) | mL/m ² | 21.1 | 13.1 | 17.9 | 7.2 | 28.8 | 18.6 | 30.5 | 21.6 | 40.4 | 21.6 |
| | AVpV | m/s | 1.4 | 0.5 | 1.3 | 0.4 | 1.7 | 0.8 | 1.5 | 0.8 | 1.4 | 0.6 |
| | AVpGrad | mmHg | 8.9 | 9.4 | 7.4 | 5.6 | 14.3 | 15.6 | 11.4 | 14.4 | 9.0 | 10.2 |
| FOLIO | ARgrade | grade | 0.4 | 0.8 | 0.2 | 0.6 | 0.7 | 1.0 | 0.5 | 0.9 | 0.9 | 1.1 |
| ECHU mogeuremente | ARjet Area | c m ² | 0.6 | 1.8 | 0.4 | 1.3 | 1.3 | 2.7 | 0.9 | 1.9 | 1.4 | 2.7 |
| measurements | MVGE mean | mmHg | 2.0 | 1.4 | 1.8 | 1.1 | 2.5 | 1.9 | 2.5 | 1.7 | 2.6 | 1.7 |
| | MV E Vmax | m/s | 0.8 | 0.3 | 0.8 | 0.2 | 0.9 | 0.3 | 0.9 | 0.3 | 0.9 | 0.3 |
| | MV A Vmax | m/s | 0.8 | 0.3 | 0.8 | 0.2 | 0.8 | 0.4 | 0.7 | 0.4 | 0.6 | 0.4 |
| | MV E/A | | 1.1 | 0.4 | 1.0 | 0.4 | 1.1 | 0.6 | 1.2 | 0.5 | 1.5 | 0.8 |
| | MRgrade | grade | 1.4 | 1.1 | 1.1 | 1.0 | 2.0 | 1.0 | 2.1 | 1.2 | 2.5 | 1.1 |
| | MRjet/LAA | % | 13.5 | 15.1 | 10.6 | 12.7 | 20.0 | 16.7 | 23.5 | 21.5 | 28.1 | 18.5 |
| | TRgrade | grade | 1.2 | 1.0 | 0.9 | 0.9 | 1.8 | 1.1 | 1.6 | 1.2 | 2.0 | 1.2 |
| | TRjet/RAA | % | 12.5 | 16.1 | 9.5 | 13.8 | 21.1 | 19.2 | 18.6 | 17.9 | 24.1 | 18.0 |
| | RVSP (mPAP) | mmHg | 18.9 | 11.8 | 16.3 | 8.3 | 26.5 | 15.8 | 24.8 | 16.6 | 29.5 | 18.1 |
| | PEEF (maximum) | mm | 0.3 | 1.7 | 0.2 | 1.5 | 0.5 | 2.2 | 0.3 | 1.6 | 0.8 | 2.3 |
| | RVOTend-distal | mm | 30.4 | 16.2 | 28.2 | 13.4 | 35.3 | 19.8 | 38.3 | 21.9 | 43.4 | 25.6 |
| | RVOTprox | mm | 26.8 | 5.8 | 25.9 | 5.5 | 29.0 | 5.4 | 29.2 | 6.2 | 30.4 | 7.2 |
| | RVDd M-mode | mm | 29.2 | 5.1 | 28.3 | 4.7 | 31.3 | 5.2 | 32.0 | 5.9 | 33.6 | 6.8 |
| | RVDs M-mode | mm | 14.3 | 4.9 | 13.5 | 4.2 | 16.3 | 5.6 | 16.6 | 6.6 | 17.9 | 7.7 |
| t | • | | | | | | | | | | | |

| | RAD (A4C) | mm | 38.4 | 7.5 | 36.7 | 6.1 | 42.6 | 8.4 | 43.0 | 9.6 | 48.4 | 9.8 |
|--------------|---------------------------|-------------------|-------|------|-------|------|---------------|------|-------|------|---------------|------|
| | RADI (RAD / BSA) | mm/m ² | 20.4 | 4.2 | 19.5 | 3.4 | 22.6 | 5.0 | 22.5 | 5.7 | 24.9 | 6.0 |
| | WM-score | score | 0.3 | 0.7 | 0.2 | 0.5 | 0.5 | 1.1 | 0.7 | 1.0 | 0.9 | 1.3 |
| | H ₂ FPEF Score | score | 2.43 | 1.39 | 1.93 | 0.82 | 3.94 | 1.63 | 3.49 | 1.67 | 3.93 | 1.73 |
| | HFA-PEFF score | score | 1.62 | 0.89 | 1.26 | 0.54 | 2.61 | 0.84 | 2.55 | 0.92 | 3.16 | 0.95 |
| | LVH | | 14.0% | | 7.8% | | 34.6 % | | 22.9% | | 33.6% | |
| | DCM | | 9.9% | | 3.7% | | 15.2% | | 44.3% | | 76.0 % | |
| | RVE | | 4.6% | | 2.2% | | 8.9% | | 12.5% | | 25.3% | |
| | LAE | | 8.8% | | 0.5% | | 29.7% | | 30.6% | | 54.3 % | |
| | RAE | | 6.5% | | 1.2% | | 17.7% | | 24.2% | | 42.8 % | |
| | WMA | | 4.5% | | 0.6% | | 4.5% | | 38.3% | | 44.1 % | |
| | LVSD | | 2.6% | | 0.0% | | 0.0% | | 0.9% | | 100.0% | |
| | DD Impaired Relaxation | | 22.7% | | 20.2% | | 35.1% | | 19.6% | | 15.8% | |
| ECHO-Finding | DD Pseudo-normal | | 3.5% | | 2.0% | | 6.5% | | 9.2% | | 11.5% | |
| | DD Restrictive Filling | | 2.9% | | 1.1% | | 7.1% | | 6.9% | | 15.8% | |
| | AS | | 5.7% | | 1.8% | | 20 .1% | | 10.5% | | 7.9% | |
| | MS | | 2.8% | - | 1.1% | | 8.4% | | 7.9% | | 4.6% | |
| | AR | | 7.0% | | 4.2% | | 15.4% | | 10.5% | | 24.0% | |
| | MR | | 12.7% | | 6.6% | | 27.3% | | 31.2% | | 48.4% | |
| | TR | | 9.9% | - | 4.6% | | 24.1% | - | 22.0% | | 36.8% | |
| | PH | | 3.7% | | 0.3% | | 12.5% | | 12.7% | | 21.1% | |
| | Abnormal ECHO | | 35.1% | | 17.7% | | 81.3% | | 93.1% | | 100.0% | |
| | S. Bradycardia | | 3.2% | | 3.5% | | 2.9% | | 1.7% | | 1.6% | |
| | S. Tachycardia | | 1.3% | | 1.3% | | 1.2% | | 1.9% | | 2.6% | |
| | AFib | | 8.2% | | 0.0% | | 33.6% | | 23.9% | | 33.6% | |
| | PVC | | 15.3% | | 10.4% | | 26.5% | | 30.6% | | 45.7% | |
| | PAC | | 14.8% | - | 12.9% | | 19.8% | | 21.2% | | 20.4% | |
| | Prolonged PR | | 3.2% | | 3.0% | | 3.6% | | 3.3% | | 6.3% | |
| | Prolonged QT | | 0.8% | | 0.6% | | 1.8% | | 1.7% | | 0.0% | |
| | BBB | | 7.7% | | 5.5% | | 13.1% | | 13.8% | | 21.1% | |
| ECG-Finding | ST-T deviation | | 17.9% | | 10.4% | | 34.9% | | 45.5% | | 53.0% | |
| | Ischemic ST-T | | 25.2% | | 17.5% | | 43.6% | | 50.8% | | 64.5% | |
| | MI criteria | | 15.7% | | 11.8% | | 24.3% | | 28.1% | | 39.5% | |
| | LVH criteria | _ | 9.1% | - | 5.1% | - | 18.6% | - | 23.9% | - | 27.0% | |
| | RVH criteria | | 0.4% | - | 0.1% | | 1.1% | - | 1.0% | | 1.6% | |
| | Leftward Axis | | 9.6% | | 6.6% | | 16.5% | | 19.1% | | 29.3% | |
| | Rightward Axis | | 1.7% | | 1.4% | | 2.3% | | 2.0% | | 4.3% | |
| | Abnormal ECG | | 40.9% | | 28.6% | | 72.4% | | 78.8% | | 92.8% | |
| | Borderline ECG | | 25.0% | | 28.4% | | 16.4% | | 16.3% | | 5.3% | |

5 6 7 8 9 10 $\begin{array}{c}
11\\
12\\
13\\
14\\
15\\
16\\
17\\
18\\
19\\
\end{array}$ $\overline{20}$ 21

(Abbreviations: AFib, Atrial Fibrillation; AR, Aortic Regurgitation; ARgrade, Grade of Aortic Regurgitation; ARjet Area, Aortic Regurgitation Jet Area; AS, Aortic Stenosis; AVpGrad, Aortic Valve Pressure; AVpV, Aortic Valve Peak Velocity; BBB, Bundle Branch Block; BMI, body mass index; BSA, body surface area; DCM, Dilated Cardiomyopathy; DD, Diastolic Dysfunction; ECG, Electrocardiogram; ECHO, Echocardiogram; HF. Heart Failure HFmrEF. Heart Failure with mildly reduced LVEF: HFpEF. Heart Failure with preserved LVEF: HFrEF. Heart Failure with reduced LVEF: HR. heart rate: IVSd. End-diastolic Interventricular Septum Thickness; LAE. Left Atrial Enlargement: LAV. Left Atrial Volume: LAVI, Left Atrial Volume Index; LF/HF (0.15Hz), Low per high frequency parts of RR int. spectrum; LVEF, Left Ventricular Ejection Fraction (Teichholz); LVH, Left Ventricular Hypertrophy; LVIDd, End-diastolic Left Ventricular Diameter; LVIDs, Endsystolic Left Ventricular Diameter; LVmass, Left Ventricular Mass; LVMI, Left Ventricular Mass Index; LVSD, Left Ventricular Systolic Dysfunction; M – Mean value; MI, Myocardial Infarction; MR, Mitral Regurgitation; MRgrade, Grade of Mitral regurgitation; MRjet/LAA, Mitral Regurgitation Jet Ratio in Left Atrium; MS, Mitral Stenosis; MV A Vmax, Mitral Inflow A Wave Velocity; MV E Vmax, Mitral Inflow E Wave Velocity; MV E/A, E/A Wave Velocity; MVGE mean, Mitral Valve Pressure E wave; PAC, Premature Atrial Complex; PEEF, Pericardial Effusion Maximum Diameter; PH, Pulmonary Hypertension; PVC, Premature Ventricular Complex; RAD, Transversal Diameter of the Right Atrium; RADI, Right Atrial Diameter Index: RAE, Right Atrial Enlargement: RAV, Right Atrial Volume: RAVI, Right Atrial Volume Index: RR std. Standard Deviation of RR intervals: Rsum (V1:V6). Summary of R amplitude V1-V6; RVDd. End-diastolic Right Ventricular Diameter; RVDs. Endsystolic Right Ventricular Diameter; RVE, Right Ventricular Enlargement; RVH, Right Ventricular Hypertrophy; RVOTend-distal, Right Ventricular Outflow Tract Distal; RVOTprox, Right Ventricular Outflow Tract Proximal; RVSP, Right Ventricular Systolic Pressure; RWT, Relative Wall Thickness; STD standard deviation; Taxis, T wave axis; TR, Tricuspid Regurgitation; TRgrade, Grade of Tricuspid Regurgitation; TRjet/RAA, Tricuspid 22 Regurgitation Jet Ratio in Right Atrium; WMA, Wall Motion Abnormality; WM-score, Wall Motion Score)

| | Primary criteria according to ESC Guideline, 2021 [1] | | | Secondary criteria according to statistical analysis | | | | |
|------------------------|--|------------------|--|---|--|--|--|--|
| HF category | Symptoms ± Signs criteria | LVEF criteria | Structural / Functional criteria | wider definition in database - applied for categorization | Typical co-morbidities ("+" denotes the disease plus the previous ones) | | | |
| Absent | No | | - | - | Non-significant or mild abnormalities | | | |
| HFpEF | Yes | ≥50% | LVH and/or LAE and/or DD | symptomatic AFib symptomatic PH symptomatic AS or MS symptomatic CAD or WMA | Regional WMA Valve diseases (AS, AR) PH Arrhythmia (AFib) Ischemic ST-T Leftward Axis | | | |
| HFmrEF | Yes | 41-49% | Global Mild LVSD | mild ALVSD with LVEF<50%, but confirmed with risk factors, HF scores and co-morbidities of WMA or LAE or LVH | + Mild Dilated LV + Global WMA <mark>+ More severe ischemia (CAD)</mark> | | | |
| HFrEF | Yes | ≤40% | Global LVSD | ALVSD with LVEF<40%, but confirmed with risk factors, HF scores and co-morbidities | + Dilated LV (DCM) + More severe valve diseases + Right Heart Enlargement | | | |
| Color Legend: | | | | | | | | |
| Primarily ECG finding | | | | | | | | |
| Mixed ÉCG/ECHO finding | | | | | | | | |

| Table 2 – HI | F category and | related ECHC | and ECG-based | co-morbidities a | nd abnormalities |
|--------------|----------------|--------------|---------------|------------------|------------------|
|--------------|----------------|--------------|---------------|------------------|------------------|

(Abbreviations: AFib, Atrial Fibrillation; ALVSD, Asymptomatic LVSD; AR, Aortic Regurgitation; AS, Aortic Stenosis; CAD, Coronary Artery Disease; DCM, Dilated Cardiomyopathy; DD, Diastolic Dysfunction; ECG, Electrocardiogram; ECHO, Echocardiogram; HF, Heart Failure; HFmrEF, Heart Failure with mildly reduced LVEF; HFpEF, Heart Failure with preserved LVEF; HFrEF, Heart Failure with reduced LVEF; LAE, Left Atrial Enlargement; LVEF, Left Ventricular Ejection Fraction; LVH, Left Ventricular Hypertrophy; LVSD, Left Ventricular Systolic Dysfunction; MS, Mitral Stenosis; PH, Pulmonary Hypertension; WMA, Wall Motion Abnormality)

| Reference categories of HF - specifically for indication in primary care | Primary criteria | Secondary criteria | CHART findings | |
|---|--|---|---|--|
| "Consider HFpEF" | symptomatic HF with LVEF>50%, and DD or LAE or LVH | symptomatic AFib symptomatic PH symptomatic AS or MS symptomatic CAD or WMA | AFib by ECG PH by Al AS, MS by Al Ischemic ST-T by ECG, WMA by Al | |
| "Consider HFmrEF" | symptomatic HF with LVEF<50% | mild ALVSD with LVEF<50%, but confirmed with risk factors, HF scores and co- morbidities of WMA or LAE or LVH | mild LVSD by Al WMA by Al, LAE by Al LVH by Al | |
| "Consider HFrEF" | symptomatic HF with LVEF<40% | ALVSD with LVEF<40%, but confirmed with risk factors, HF scores and co- morbidities | moderate LVSD by AI DCM by AI and all other ECG (BBB, ST- T) and AI-findings (RAE, RVE, MR, TR, AR) | |

Table 3 – Supporting "Consider HF" categories by CHART

(Abbreviations: AFib, Atrial Fibrillation; AI, Artificial Intelligence, ALVSD, Asymptomatic LVSD; AR, Aortic Regurgitation; AS, Aortic Stenosis; BBB, Bundle Branch Block; CAD, Coronary Artery Disease; DCM, Dilated Cardiomyopathy; DD, Diastolic Dysfunction; ECG, Electrocardiogram; HF, Heart Failure; HFmrEF, Heart Failure with mildly reduced LVEF; HFpEF, Heart Failure with preserved LVEF; HFrEF, Heart Failure with reduced LVEF; LAE, Left Atrial Enlargement; LVEF, Left Ventricular Ejection Fraction; LVH, Left Ventricular Hypertrophy; LVSD, Left Ventricular Systolic Dysfunction; MR, Mitral Regurgitation; MS, Mitral Stenosis; PH, Pulmonary Hypertension; RAE, Right Atrial Enlargement; RVE, Right Ventricular Enlargement; TR, Tricuspid Regurgitation; WMA, Wall Motion Abnormality)





